Article | July 10, 2017

Total Cost of Ownership Considerations for Biopharmaceutical Manufacturing Facilities

Source: G-CON Manufacturing

By Peter Makowensky, Dennis Powers, Maik Jornitz

Total Cost of Ownership Considerations for Biopharmaceutical Manufacturing Facilities

High-volume, product-specific facilities are becoming a thing of the past, replaced by those that can expand or be relocated on-demand, handle multiple products, and shift from a centralized to decentralized model as the market dictates. This paradigm shift has led to the evolution of the modular-built and prefabricated facility-manufacturing methods, especially in relation to clean rooms. Both of these methodologies offer significant benefits — the most important of which is total cost of ownership (TCO) — when compared to traditional “stick-built” facilities. But before we assess the cost implications and ROI of all three options, let’s first look take a closer look at what each method entails.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: